Aliu Oluseyi, Zhong Lin, Chetta Matthew D, Sears Erika D, Ballard Tiffany, Waljee Jennifer F, Chung Kevin C, Momoh Adeyiza O
Ann Arbor, Mich.
From the Section of Plastic Surgery, Department of Surgery, University of Michigan Health System.
Plast Reconstr Surg. 2017 Jun;139(6):1224e-1231e. doi: 10.1097/PRS.0000000000003336.
In the debate on reconstruction of the irradiated breast, there is little information on associated health care resource use. Nationwide data were used to examine health care resource use associated with implant and autologous reconstruction. It was hypothesized that failure rates would contribute the most to higher average cumulative cost with either reconstruction method.
From the 2009 to 2013 MarketScan Commercial Claims and Encounters database, irradiated breast cancer patients who underwent implant or autologous reconstruction were selected. In a 24-month follow-up period, the cumulative costs of health care services used were tallied and described. Regression models stratified by reconstruction method were then used to estimate the influence of failure on cumulative cost of reconstruction.
There were 2964 study patients. Most (78 percent) underwent implant reconstruction. The unadjusted mean costs for implant and autologous reconstructions were $22,868 and $30,527, respectively. Thirty-two percent of implant reconstructions failed, compared with 5 percent of autologous cases. Twelve percent of the implant reconstructions had two or more failures and required subsequent autologous reconstruction. The cost of implant reconstruction failure requiring a flap was $47,214, and the cost for autologous failures was $48,344. In aggregate, failures constituted more than 20 percent of the cumulative costs of implant reconstruction compared with less than 5 percent for autologous reconstruction.
More than one in 10 patients who had implant reconstruction in the setting of radiation therapy to the breast eventually required a flap for failure. These findings make a case for autologous reconstruction being primarily considered in irradiated patients who have this option available.
在关于放疗后乳房重建的讨论中,关于相关医疗资源使用的信息较少。利用全国性数据来研究与植入物和自体组织重建相关的医疗资源使用情况。据推测,无论采用哪种重建方法,失败率对较高的平均累计成本贡献最大。
从2009年至2013年的MarketScan商业索赔和病历数据库中,选取接受植入物或自体组织重建的放疗后乳腺癌患者。在24个月的随访期内,统计并描述所使用的医疗服务的累计成本。然后使用按重建方法分层的回归模型来估计失败对重建累计成本的影响。
共有2964例研究患者。大多数(78%)接受了植入物重建。植入物重建和自体组织重建的未调整平均成本分别为22,868美元和30,527美元。32%的植入物重建失败,而自体组织重建的失败率为5%。12%的植入物重建出现两次或更多次失败,并需要随后进行自体组织重建。需要皮瓣修复的植入物重建失败的成本为47,214美元,自体组织重建失败的成本为48,344美元。总体而言,失败构成了植入物重建累计成本的20%以上,而自体组织重建的这一比例不到5%。
在接受乳房放疗的患者中,每10例接受植入物重建的患者中就有超过1例最终因失败而需要皮瓣修复。这些发现表明,对于有自体组织重建选择的放疗患者,应首先考虑自体组织重建。